n the wake of the catastrophic West African Ebola outbreak a few years back, a group of key players in the global health sphere launched an initiative aimed at fast-tracking development of vaccines for diseases that could cause devastating outbreaks.

In a major step, that organization known as CEPI — the Coalition for Epidemic Preparedness Innovations — said this week that it has awarded its first contract, an agreement with an Austrian biotech company to develop vaccines to protect against Middle East respiratory syndrome, or MERS, and Lassa fever.

This is a STAT Plus article and you can unlock it by subscribing to STAT Plus today. It's easy! Your first 30 days are free and if you don't enjoy your subscription you can cancel any time.
Already a subscriber? Log in here.

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.